64. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virusinfected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005 Jul; 40(7):867-72.
65. Imbert-Bismut F, Ratziu V, Pieroni L.. Biochemical markers of liver fibrosis on patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357:1069–75.
66. Myers RP, Tainturier M-H, Ratziu V. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003; 39:222-30.
67. Forns X, Ampurdanes S, Llovet JM. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36:986-92.
68. Mukherjee S, Sorrell MF. Noninvasive Tests for Liver Fibrosis.Seminars in Liver Disease. 2006; 26 (4): 337-46.
69. Nyblom H, Berggren U, Balldin J, Olsson R.. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004 Jul-Aug; 39(4):336-9.
70. Pérez A. Ecografía e hígado. SEMERGEN 2003; 29 (2):78–97. 71- Murakami T, Mochizuki K, Nakamura H. Imaging Evaluation of the Cirrhotic Liver. Seminars in Liver Disease. 2001; 21(2):213:224.
71. Murakami T, Mochizuki K , Nakamura H. Imaging Evaluation of the Cirrhotic Liver. Seminars in Liver Disease. 2001; 21(2):213:224.
72. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005; 41:48-54.
73. De Franchis R. Evaluation and follow-up of patients with cirrhosis and oesophageal varices. J Hepatol. 2003; 38:361-363.
74. García Pagán JC. Diagnóstico actual de la hipertensión portal. Gastroenterol Hepatol. 2007; 30(Supl 1):1-6.
75. Bosch J, Garcia-Pagán JC, Berzigotti A, , Abraldes JG. Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. Seminars in Liver Disease. 2006; 26(4) 2006:349-362.
76. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000; 32:930-4.
77. Turnes J, García-Pagán JC, Abraldes JG, Hernández-Guerra M, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006; 101:506-12.
78. Division of Epidemiological Surveillance and Health Situation and Trend Assessment Global Estimates for Health Situation: Assessment and Project—1990. Geneva: World Health Organization; 1990.
79. Manos MM, Leyden WA, Murphy RC, Terrault NA, Bel BP. Limitations of Conventionally Derived Chronic Liver Disease Mortality Rates: Results of a Comprehensive Assessment. Hepatology. 2008; 47:1150-57.
80. Savolainen VT, Penttila A, Karhunen PJ. Delayed increases in liver cirrhosis mortality and frequency of alcoholic liver cirrhosis following an increment and redistribution of alcohol consumption in Finland: evidence from mortality statistics and autopsy survey covering 8533 cases in 1968–1988. Alcohol Clin Exp Res. 1992; 16:661–64.
81. Méndez- Sánchez N, Almeda- Valdés P, Uribe M. Alcoholic liver disease. An update. Annals of Hepatology. 2005; 4(1):32-42.
82. Korean National Statistical Office. Annual Report on the Causes of Death Statistics. Seoul 1999:25-7.
83. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci. 2002; 17:457-62.
84. Dirección Nacional de Estadística. Anuario Estadístico de Salud de Cuba, 2007, [página en Internet] 2008 [consultado junio 27, 202012]. Disponible en: http://www.sld.cu/sitios/dne/
85. Nelson D, Rustgi V, Balan V, Sulkowski M, Lambiaise L, Dickson R. Week 12 and beyond antiviral activity of higher doses of albuferon combined with ribavirin in non-responders to prior interferon based therapy for chronic hepatitis C infection Gastroenterology. 2006; 130 Suppl 2:A-754.
86. Afdhal N, Jacobsen I, Brown R, Freilich B, Santoro J, Griffel L, et al. The effects of liver fibrosis and cirrhosis on SVR in 4913 patients with hepatitis C: Results from the WinC trial. Gastroenterology. 2006; 130 (Suppl 2:A):771.
87. Prieto M, Aguilera V, Berenguer M, Rubín A, Benlloch S y Aguas M. Actualización del trasplante hepático en la hepatitis C crónica. Gastroenterol Hepatol. 2007; 30(Supl 1):62-9.
88. Samada M, Hernández JC, González L, Ramos L. Aspectos específicos relacionados con el trasplante hepático en las hepatopatías por virus C. Rev Cub Med Mil [Revista en Internet] 2005 Jun.[citado03 de julio de 2012]; 34(2). Disponible en: http://scielo.sld.cu/scielo.php?script= sci_arttext&pid=S0138- 65572005000200009&lng=es&nrm=iso
89. Ripoll C, Bañares R, Rincón D, Catalina MV, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology. 2005; 42:793-801.
90. Wang YW; Yang YY; Lin HC; Lee PC; Hou MC; Lee FY et al. Model for endstage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int. 2007 May; Vol. 27 (4):498-506.
91. Heuman D, Habib A, Gilles H, Fisher RA, Mihas AA. Importance of ascites abd hyponatremia as predictors of pre-transplant survival in the MELD era: results of a two-year prospective validation in cirrhotic veterans. Gastroenterology. 2006; 130 Suppl 2:A-761.
92. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl. 2007; 13 (10):1366-71.p://www.sld.cu/sitios/dne/
93. Christensen E. Prognostic models in chronic liver disease: validity, usefulness and future role. J Hepatology. 1997;26:1414-24.
94. Orlandi F, Christensen E. A consensus conference on prognostic studies in Hepatology. J Hepatol. 1999;30:171-2.
95. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. Journal of Hepatology 2005; 42:S100-S107.
96. Mishra P, Desai N, Alexander J, Singh DP , Sawant P. Applicability of MELD as a short-term prognostic indicator in patients with chronic liver disease: An Indian experience. Journal of Gastroenterol and Hepatol. 2007; 22:1232-35.
97. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004; 40:897–903.
98. Vargas V y Ortiz M. Modelos pronósticos en la cirrosis hepática. El modelo MELD. Gastroeterol Hepatol. 2003; 26(4):257-9.
99. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. [Página en Internet] 2004 [citado 8 de Julio de 2008]; disponible en: www.wma.net/s/policy/b3.htm